response to various stimuli within the coronary arteries were enhanced. [7] [8] [9] [10] These findings attributed the hyperactivity of the coronary artery smooth muscle to intracellular and/or postreceptorial mechanisms. 11 Phospholipase C (PLC) correlates with the contraction of coronary arteries and is a vital molecule in the intracellular calcium regulation. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP 2 ) to produce inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol. IP 3 mobilizes Ca 2+ from the intracellular stores and exhibits rapid contraction of the vascular smooth muscle, 12 whereas diacylglycerol activates protein kinase C and triggers the sustained muscle contraction via a Ca 2+ -independent mechanism. 13 Previously, we have reported the enhanced PLC activity in cultured skin fibroblasts obtained from patients with CSA and determined that a major PLC isozyme in the membrane fraction was the δ1 isoform, which is more sensitive to Ca 2+ than other isozymes.
14 Furthermore, we have demonstrated the presence of a G to A mutation at nucleotide position 864 in PLC-δ1 in patients with CSA, accompanied by the amino acid (aa) replacement of arginine 257 to histidine (R257H), which markedly enhanced the PLC enzymatic activity in the physiological range of the intracellular free calcium concentration ([Ca 2+ ] i ). 15 To elucidate its role in coronary spasm, we created mice that overexpressed the variant PLC-δ1 (R257H) under the control of the mouse α-SMA promoter and illustrated that the elevated PLC-δ1 activity enhanced coronary vasomotility, as observed in patients with CSA. 16 A study has demonstrated that p122RhoGTPase-activating protein (GAP)/deleted in liver cancer-1 (p122RhoGAP/ DLC-1), cloned as a PLC-δ1-interacting protein from a rat brain expression library, exhibits a specific GTPase-activating protein (GAP) activity on Rho, augmenting the PIP 2 hydrolyzing activity of PLC-δ1 in vitro. 17 Further, this rat p122RhoGAP/DLC-1 was reportedly the ortholog of human p122RhoGAP/DLC-1, with an aa sequence identity of 93%. [18] [19] [20] In addition, p122RhoGAP/DLC-1 is acknowledged as a tumor suppressor and is downregulated in several malignant cancer types, including colorectal, breast, prostate, and liver cancer. 21 Previously, we have reported that the p122RhoGAP/DLC-1 protein expression in cultured skin fibroblasts obtained from patients with CSA was upregulated threefold compared with that in control fibroblasts, and the p122RhoGAP/DLC-1 overexpression increased [Ca 2+ ] i in response to acetylcholine (ACh). 22 Furthermore, we created mice that overexpressed p122RhoGAP/DLC-1 and illustrated that the coronary spasm was induced by injecting ergometrine into the jugular vein. 23 These findings revealed that the p122RhoGAP/DLC-1 upregulation in coronary arteries is attributable to the coronary spasm pathogenesis associated with human CSA. Nevertheless, the regulatory mechanisms and physiological functions of p122RhoGAP/ DLC-1 and PLC-δ1 remain partially understood. The present study aims to identify a novel protein that interacts with p122RhoGAP/DLC-1 and PLC-δ1 and elucidate its role in the CSA pathogenesis.
| MATERIALS AND METHODS

| Patients
This study protocol was approved by the Ethics Committee of our institution, and we obtained written informed consent from all patients before the study. Our study cohort comprised 8 Japanese patients with CSA (7 male and 1 female; mean age: 58 ± 6 years) and 6 control subjects without hypertension or any history suggestive of angina pectoris (3 male and 3 female; mean age: 52 ± 6 years). All patients with CSA underwent coronary arteriography with an intracoronary administration of ACh to induce coronary spasm, defined as the total or subtotal occlusion or severe vasoconstriction of the coronary artery related to chest pain and ischemic change on ECG. After an intracoronary injection of isosorbide dinitrate, coronary arteriograms revealed normal or almost normal coronary arteries with diameter stenosis ≤50% of the lumen diameter in all patients with CSA.
| Cell culture
We prepared human skin fibroblasts using the explant method, as described previously. 14 The fibroblasts and HEK293 cells were cultured in Dulbecco's modified Eagle's medium (#11965-092; Gibco, NY) supplemented with 10% FBS (#12483-020; Gibco, MA), penicillin (100 U/mL), and streptomycin (100 μg/mL; #168-23191; FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) at 37°C under 5% CO 2 and 95% air.
| Immunoprecipitation
We extracted skin fibroblasts with Pierce IP Lysis Buffer (87787; ThermoFisher, MA, USA) containing a protease inhibitor cocktail (78429; ThermoFisher, MA). The cell debris was removed from the lysates by centrifuging at 13 000 rpm for 15 minutes at 4°C, followed by preclearing with Dynabeads G (DB10003; Dynal Biotech, Oslo, Norway). We added the Dynabeads G (50 μL) to the anti-p122RhoGAP/DLC-1 antibody (612020; BD Biosciences, CA), anti-IQGAP1 antibody (610611; BD Biosciences), or normal mouse IgG, incubated for 2 h at 4°C, and washed with phosphate-buffered saline (PBS) with 0.02% Tween 20. Next, the cell lysates were added and incubated overnight at 4°C. After incubation, we washed the immunoprecipitates three times with PBS with 0.02% Tween 20 and eluted the immobilized immunocomplexes with a sample-treating solution containing 2% SDS and 5% β-mercaptoethanol for 30 minutes at 50°C. Then, the eluted proteins were fractionated by SDS-PAGE and detected with a Silver Stain MS Kit (299-58901; FUJIFILM Wako Pure Chemical Corporation, Osaka, Japan) or by Western blotting.
| Mass spectrometry analysis
We analyzed protein bands (molecular weight range: 150-250 kDa) that interacted with the p122RhoGAP/DLC-1 peptide in an immunoprecipitation assay using skin fibroblasts by TOF-MS (Oncomics Co., Ltd.).
| Plasmid construction and transfection
The cDNA for human pEGFP (enhanced green fluorescent protein)-C2-IQGAP1, pGEX-IQGAP1-N (1-863), and pGEX-IQGAP1-C (746-1657) were kindly provided by Dr Kozo Kaibuchi (Department of Cell Pharmacology, Nagoya University Graduate School of Medicine, Nagoya, Japan). To express p122RhoGAP/DLC-1, the cDNA was amplified by a polymerase chain reaction from a human brain cDNA library (Clontech, CA) using an appropriate primer pair. To express proteins tagged with an epitope at the N terminus in human cells, we inserted the IQGAP1 and p122RhoGAP/DLC-1 cDNA into the plasmid vector pcDNA3/RH-N 24 to create pcDNA3/RH-IQGAP1 and pcDNA3/RH-p122RhoGAP/DLC-1. We subcloned cDNA fragments corresponding to each p122RhoGAP/ DLC-1 fragment into pTrcHisA to obtain p122RhoGAP/DLC-1 (aa 1-1079), p122RhoGAP/DLC-1 (aa 1-546), p122RhoGAP/ DLC-1 (aa 1-801), and p122RhoGAP/DLC-1 (aa 547-1079). Furthermore, pEGFP-C2-IQGAP1 and pcDNA3/RHp122RhoGAP/DLC-1 plasmids were transfected into HEK293 cells using Lipofectamine 3000 (Invitrogen, MA, USA).
| RNA interference
HEK293 cells were transfected with p122RhoGAP/DLC-1 siRNA (sense, 5′-GAAACGCCUUAAGACACUATT-3′; antisense, 5′-UAGUGUCUUAAGGC GUUUCTT-3′; TaKaRa Biotechnology Co., Ltd., Kyoto, Japan), IQGAP1 siRNA (s16837; Applied Biosystems, CA, USA), or negative control. The cells were transfected by siRNA (final concentration: 100 nmol/L) at 70%-80% confluency using a transfection reagent, DharmaFECT Duo (T-2010-03; Dharmacon, CO), in the complete medium, as per the manufacturer's instructions.
| Western blotting
We treated the whole-cell protein samples for 30 minutes at 50°C in a sample-treating solution containing 2% SDS and 5% β-mercaptoethanol. We followed the protocol provided for the Plasma Membrane Protein Extraction Kit (BioVision, CA, USA) to extract the PM protein. Next, protein samples were separated by SDS-PAGE and electrophoretically transferred to a polyvinylidene fluoride membrane (Bio-Rad Laboratories, Hercules, CA). After 1-h blocking, we incubated the membranes overnight at 4°C with the primary antibodies for IQGAP1, p122RhoGAP/DLC-1, PLC-δ1 (ab134936; Abcam, CB, UK), and GAPDH (sc-25778S; Santa Cruz Biotechnology, TX, USA). We used a horseradish peroxidase-conjugated antibody (Santa Cruz Biotechnology) as a secondary antibody. After SDS-PAGE, we performed Western blotting per the protocol provided with the ECL (Enhanced Chemiluminescence) Detection System (GE Healthcare, IL, USA). Furthermore, we performed densitometric analysis with Scion imaging software and evaluated the relative ratio to GAPDH for each sample.
| Fluorescence microscopy
We performed fluorescence microscopy studies to investigate the subcellular locations in skin fibroblasts of IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1. Skin fibroblasts were cultured on a 3. response at excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm, as described previously. 25 We used ACh because it is extensively used to induce coronary spasm in Japanese patients. 26 Furthermore, calibration was performed using ionomycin followed by EGTA-Tris.
| Measurement of the PLC activity
The PLC assay system comprised the following components: N-2-hydroxyethylpiperazin-N′-2-ethanesulfonic acid (50 mmol/L); calcium chloride (0.1 mmol/L); sodium cholate (9 mmol/L); tritium-PIP 2 (40 000 counts/min); and the cell protein (100 μg). The reaction was discontinued with a | TANAKA eT Al.
combination of chloroform, methanol, and hydrogen chloride, followed by 1-N hydrogen chloride containing EGTA. After extraction, we removed the aqueous phase for liquid scintillation counting.
| In vitro interaction assay
Several recombinant proteins were first expressed in Escherichia coli (BL21 DE333) using the eukaryotic expression vectors pGEX-and pTrcHisA-, as described previously. 27, 28 Then, GST-fused IQGAP1-N and IQGAP1-C were purified using Glutathione Sepharose 4B (17-0756-01; GE Healthcare, CT, USA). Next, we centrifuged the bacterial crude lysates containing p122RhoGAP/DLC-1 (aa 1-1079), p122RhoGAP/DLC-1 (aa 1-546), p122RhoGAP/DLC-1 (aa 1-801), p122RhoGAP/ DLC-1 (aa 547-1079), and PLC-δ1 (1-756) at 14 00× g for 5 minutes and incubated the supernatants for 3 hours at room temperature with GST fusion proteins immobilized on Glutathione Sepharose beads. Then, the beads were washed six times with the lysis buffer, and the proteins precipitated on the beads were eluted in 2% SDS treating solution. Finally, we subjected them to Western blotting using a mouse anti-RH monoclonal antibody (specific to the aa sequence RGSHHHHHH).
| Localization of PLC-δ1, IQGAP1, and p122RhoGAP/DLC-1
We cultured HEK293 cells in 10-cm culture plates at a density of 5 × 10 6 cells/dish. After 24-h incubation, the cells were serumstarved for 16 hours and stimulated with ACh (10 −4 mol/L) for 5 minutes. We cultured skin fibroblasts and stimulated them with ionomycin (10 −5 M) for 5 minutes. Then, we extracted CY and PM proteins using the PM Protein Extraction Kit (BioVision, CA, USA). The protein samples were treated for 30 minutes at 50°C in a sample-treating solution containing 2% SDS and 5% β-mercaptoethanol, followed by subjecting them to Western blotting. Furthermore, we assessed the localization of PLC-δ1, IQGAP1, and p122RhoGAP/DLC-1 by a cell preparation method similar to fluorescence microscopy.
| RhoA-GTP pull-down assay
We measured the RhoA activity using an Active Rho Detection Kit (Cell Signaling Technology, MA, USA), per the manufacturer's protocol. Then, HEK293 cells were subcultured in 6-cm Petri dishes and transfected with pEGFP-C2-IQGAP1, pcDNA3/RH-p122, or an empty vector (1.0 μg DNA/well for all). Finally, the cells were serum-starved for 16 hours and, then, stimulated with 10% FBS for 5 minutes to activate RhoA.
| Statistical analysis
In this study, data were analyzed using the statistical software JMP (version 11.0) and were expressed as mean ± standard deviation. We tested comparisons of two variables using paired or unpaired t-tests, as appropriate, as well as multiple comparisons using the Tukey-Kramer test. Of note, P < 0.05 was considered statistically significant.
| RESULTS
| p122RhoGAP/DLC-1 protein expression in cultured fibroblasts
We detected the p122RhoGAP/DLC-1 protein using 4%-20% gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel in a single band around 122 kDa, and its expression was increased in patients with CSA as anticipated ( Figure 1A ). Remarkably, we detected an unknown band around 200 kDa (150-250 kDa) above the p122RhoGAP/DLC-1 protein band in patients with CSA after prolonged exposure; as this unknown band was detected with a specific antibody against p122RhoGAP/DLC-1, we assumed it to be a heterodimer of p122RhoGAP/DLC-1 and its binding protein.
In addition, the molecular weight of p122RhoGAP/DLC-1-binding protein was estimated to be approximately 80 kDa (difference between 200 and 122 kDa). Furthermore, the expression of this unknown band was higher in patients with CSA than that in control subjects.
| Identification of p122RhoGAP/DLC-1-binding proteins
We performed immunoprecipitation assay of p122Rho-GAP/DLC-1 using CSA skin fibroblasts to analyze the unknown protein mentioned in the section above. Electrophoresis was carried out using 7.5% gel to expand the range of 150-250 kDa. Several proteins bound specifically to p122RhoGAP/DLC-1 were detected by an immunoprecipitation assay with skin fibroblast lysate and visualized by silver staining ( Figure 1B ). Of them, proteins around 200 kDa (150-250 kDa) were characterized by using the time of flight mass spectrometry (TOF-MS) method using TripleTOF 5600 (AB Sciex Pte. Ltd.) and then by entering the resulting data into a search of the NCBI database by using ProteinPilot™ 
| Interaction of IQGAP1 with p122RhoGAP/DLC-1 and PLC-δ1 in skin fibroblasts
The mass spectrometry analysis revealed that IQGAP1 interacts with p122RhoGAP/DLC-1; using immunoprecipitation, 29 we identified this interaction in skin fibroblasts obtained from control subjects and patients with CSA. The IQGAP1-specific immunoprecipitation elute was immunoblotted with p122RhoGAP/DLC-1 and PLC-δ1 antibodies ( Figure 1D and 1). We detected the bands corresponding to these molecules in an IQGAP1 immunoprecipitate, establishing the correlation of p122RhoGAP-DLC-1 and PLC-δ1 with IQGAP1. Of note,
F I G U R E 1
The identification of p122RhoGAP/DLC-1-binding protein and interaction of IQGAP1 with p122RhoGAP/DLC-1 and PLC-δ1 in skin fibroblasts. A, The human p122RhoGAP/DLC-1 and GAPDH protein expression using 4%-20% gradient sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gel in skin fibroblasts of control subjects (n = 3) and patients with coronary spastic angina (CSA; n = 6). To detect unknown signal intensities, Western blotting was additionally exposed for a prolonged duration (long exposure, 10 min). B, Skin fibroblasts cell lysates obtained from CSA were immunoprecipitated using a normal mouse IgG and an anti-p122RhoGAP/DLC-1 mouse monoclonal antibody, fractionated by 7.5% SDS-PAGE, and detected with silver staining followed by time of flight mass spectrometry (TOF-MS) analysis of p122RhoGAP/DLC-1 peptide-interacting proteins. C, D, and E, Cell lysates immunoprecipitated with an anti-IQGAP1 mouse monoclonal antibody or with and without normal mouse IgG. C, The IQGAP1 IP elute is resolved on SDS-PAGE and immunoblotted using an IQGAP1 antibody. D, The IQGAP1 IP elute is resolved on SDS-PAGE and immunoblotted using a p122RhoGAP/DLC-1 antibody. E, The IQGAP1 IP elute is resolved on SDS-PAGE and immunoblotted using a PLC-δ1 antibody. IP, immunoprecipitation PLC-δ1-like bands on the lanes of no anti-IQGAP1 antibody or IgG in Figure 1E were nonspecific (molecular weight of PLC-δ1-like bands is higher than that of PLC-δ1).
| Subcellular localization of p122Rho-GAP/DLC-1, IQGAP1, and PLC-δ1 in skin fibroblasts
As the immunoprecipitation study illustrated the interaction of IQGAP1 with p122RhoGAP/DLC-1 and PLC-δ1, we hypothesized that these proteins would be colocalized in skin fibroblasts. As shown in Figure 2Aa , 2Ba, 2Ec, 2Ac, 2Cc, and 2Dc, IQGAP1 and p122RhoGAP/DLC-1 were localized in the nucleus and in the cytoplasm. To elucidate these points, we chose an extended flat area of the cell and magnified images of the two proteins. IQGAP1 and p122RhoGAP/DLC-1 were arranged in small dots and created a structure of linear arrays in the cytoplasm (Figure 2A, b and d) . Upon merging these images, the linear arrays of IQGAP1 and p122RhoGAP/ DLC-1 were colocalized in the cytoplasm (Figure 2A, f) . IQGAP1 was primarily localized in the nucleus as small dots and created slight linear arrays in the cytoplasm ( Figure  2B , a). PLC-δ1 was primarily detected in the cytoplasm as small dots and only to a small extent in the nucleus ( Figure  2B, c) . The small dots of PLC-δ1 created fine linear arrays, similar to microtubules, which were colocalized in the cytoplasm with the linear arrays of IQGAP1 ( Figure 2B, e) . Once more, we chose an extended flat area of the cell and magnified the images; merging these revealed that the small dots of IQGAP1 were located along the arrays of PLC-δ1 ( Figure  2B, d, d, and f) .
Small dots of PLC-δ1 and p122RhoGAP/DLC-1 created fine linear arrays like microtubules ( Figure 2C , a-d); these were colocalized in the cytoplasm. Merging magnified images of an extended flat area of the cell revealed that the linear arrays of dots of p122RhoGAP/DLC-1 were located along the arrays of PLC-δ1 ( Figure 2C, f) .
| Location of p122RhoGAP/DLC-1,
IQGAP1, and PLC-δ1 along microtubules
As explained above, p122RhoGAP/DLC-1, IQGAP1, and PLC-δ1 displayed linear arrays and, perhaps, could be involved in the transport system along microtubules; this observation led us to compare the distributions of p122RhoGAP/ DLC-1, IQGAP1, PLC-δ1, and the microtubule network. Accordingly, we double-immunostained p122RhoGAP/ DLC-1, IQGAP1, or PLC-δ1 in skin fibroblasts, as well as α-tubulin for the microtubule network, and ascertained their distributions by fluorescence microscopy. The α-tubulin created a fine network of microtubules ( Figure 2D, a, 2, a, and 2, a) . We observed p122RhoGAP/DLC-1 in the form of cytoplasmic bodies ( Figure 2D, c) . Figure 2D, b and d) . Merging the images displayed an abundance of p122RhoGAP/DLC-1 cytoplasmic bodies along the microtubule network ( Figure 2D, f) . Notably, we observed p122RhoGAP/DLC-1 cytoplasmic bodies to be partially located along microtubules; similarly, IQGAP1 and PLC-δ1 were observed as cytoplasmic bodies ( Figure 2E, c  and 2, c) . For clarification, we selected an extended flat area of the cell and magnified images of the two proteins. Small dots of IQGAP1 formed fine linear arrays ( Figure 2E, d) , which in merged images were found to be located along microtubules ( Figure 2E, f) . Furthermore, small dots of PLC-δ1 formed a fine network like microtubules ( Figure 2F, f) . Remarkably, α-tubulin and PLC-δ1 were almost colocalized in the cytoplasm. These findings established that p122RhoGAP/DLC-1, IQGAP1, and PLC-δ1 were located along microtubules.
| IQGAP1 protein expression in cultured fibroblasts
After 16-h starvation, we scraped cultured fibroblasts to assess the IQGAP1 protein expression. The anti-IQGAP1 antibody was specific to IQGAP1 ( Figure 3A) , and IQGAP1 was strongly detected as a single band of 195 kDa just above the 150-kDa marker. Compared with control subjects, the IQGAP1-to-GAPDH protein ratio was significantly higher by 1.4 ± 0.2 times in patients with CSA (P < 0.01; Figure 3B ).
| PLC activity
In this study, the PLC enzymatic activity was increased by 1.4 ± 0.05 times in IQGAP1-transfected human embryonic kidney (HEK) 293 cells compared with those transfected with an empty vector (n = 3, P < 0.05; Figure 3C ).
| Impact of IQGAP1 transfection on the [Ca 2+ ] i response to ACh
We assessed the impact of the IQGAP1 overexpression on the ACh-induced increase in [Ca 2+ ] i using HEK293 cells. Figure  4A ] i was augmented by the IQGAP1 overexpression, which was established by Western blotting as a single immunoreactive band at 195 kDa ( Figure 4D ). The IQGAP1-to-GAPDH ratio in IQGAP1-overexpressed cells was 1.95 ± 0.15 times (n = 5, P < 0.01) compared with that in cells transfected with an empty vector rather than IQGAP1 ( Figure 4D ). The [Ca 2+ ] i levels at the baseline were 14 ± 9 nmol/L without the IQGAP1 overexpression and 53 ± 34 nmol/L with the IQGAP1 overexpression ( Figure 4B , n = 5, P < 0.05). In addition, the ACh-induced peak increase in [Ca 2+ ] i was higher in cells with the IQGAP1 overexpression than those without the IQGAP1 overexpression (134 ± 23 nmol/L vs 95 ± 10 nmol/L, n = 5, P < 0.01; Figure 4C ). The IQGAP1-to-GAPDH ratio was 79.7% ± 2.5% (n = 5, 
| In vitro interaction between IQGAP1
and p122RhoGAP/DLC-1
We conducted an in vitro interaction assay and attempted to narrow down the p122RhoGAP/DLC-1 region essential for IQGAP1 binding to confirm the interaction between IQGAP1 and p122RhoGAP/DLC-1 observed in immunoprecipitation. In addition, we conducted pull-down experiments with the p122RhoGAP/DLC-1 deletion mutants (aa 1-1091, 1-546, 1-801, and 547-1091; Figure 5B ) expressed in bacteria with glutathione S-transferase (27)-fused IQGAP1-N and IQGAP1-C ( Figure 5A ). The N-or C-terminal halves of IQGAP1 (IQGAP1-N, aa 1-863, and IQGAP1-C, aa 746-1657) were expressed as GST fusion proteins and purified from the bacteria ( Figure 5A ). Silver staining revealed that the sizes of GST-IQGAP1-N and GST-IQGAP1-C fusion proteins were 124 and 131 kDa, respectively, as anticipated ( Figure 5D ). We observed that p122RhoGAP/DLC-1 (1-1091) and p122RhoGAP/DLC-1 (547-1091) could be precipitated with GST-IQGAP1-C but not with GST-IQGAP1-N ( Figure 5E ). Furthermore, p122RhoGAP/DLC-1 (1-546) and p122RhoGAP/DLC-1 (1-801) could not be precipitated with GST-IQGAP1-C and -N ( Figure 5E ). These findings suggested that IQGAP1-C interacts through the region covering residues 802-1091 of the START domain of p122RhoGAP/ DLC-1.
| In vitro interaction between
IQGAP1 and PLC-δ1
Likewise, we conducted an in vitro interaction assay, conducting pull-down experiments with PLC-δ1 (1-756) ( Figure  5C ) expressed in bacteria with GST-fused IQGAP1-N and IQGAP1-C to confirm the interaction between IQGAP1 and PLC-δ1 observed in skin fibroblasts ( Figure 5A ). PLC-δ1 (1-756) could be precipitated with GST-IQGAP1-N but not with GST-IQGAP1-C ( Figure 5F ), indicating that PLC-δ1 interacts through the region covering residues 1-745 of the CHD and WW domain of IQGAP1. However, further studies are warranted to elucidate the exact binding domain of PLC-δ1 to IQGAP1.
| Recruitment of PLC-δ1, IQGAP1,
and p122RhoGAP/DLC-1 to the PM p122RhoGAP/DLC-1 is a PLC-δ1-interacting protein localized in lipid rafts in fibroblastic and epithelial cell lines. Reportedly, the interaction between PLC-δ1 and p122RhoGAP/DLC-1 is enhanced by treating PC12 cells with carbamylcholine. 30 By investigating the GFP-PLC-δ1-PH expression and analyzing its involvement in the endogenous IQGAP1 localization by immunostaining, Choi et al (2013) revealed that in the optimal amount of PLC-δ1-PH domain, endogenous IQGAP1 partially colocalized with GFP-PLC-δ1-PH in MDA-MB-231 cell lines. In this study, we investigated whether IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 were recruited to the PM after stimulating skin fibroblasts with ionomycin, a Ca 2+ ionophore. We treated skin fibroblasts with or without ionomycin at 10 −5 M for 5 minutes and analyzed IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 using Western blotting in the total cell lysates (TCL), cytosol (CY), and the PM fractions. No change was noted during this process in the amounts of IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 in the TCL ( Figure 6A) , nor was there a change in the amount of IQGAP1 in the CY ( Figure 6A ). However, we observed an apparent increase of IQGAP1 in the PM after the ionomycin treatment ( Figure 6A) . Similarly, the amounts of p122RhoGAP/DLC-1 and PLC-δ1 in the CY decreased after the ionomycin treatment but increased in the PM. These findings suggested that IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 in skin fibroblasts were recruited from the CY to the PM. In addition, we assessed whether IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 were recruited to the PM after stimulation with ACh in HEK293 cells. After the ACh treatment, no change was noted in the amounts of IQGAP1 and p122RhoGAP/DLC-1 in the TCL (Figure 6B) or CY, but both IQGAP1 and p122RhoGAP/DLC-1 displayed clear elevation in the PM. Notably, p122RhoGAP/ DLC-1 was not expressed in the cell membrane without the ACh treatment. The PLC-δ1 expression was very low in the TCL and exhibited no change in the CY after the ACh treatment but a marginal increase in the PM. These findings suggested that IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 moved from the CY to the PM after the ACh treatment in HEK293 cells.
Next, we assessed whether IQGAP1 siRNA was involved in ACh-induced PM recruitment of p122RhoGAP/ DLC-1 and PLC-δ1 in HEK293 cells. After transfection with IQGAP1 siRNA, the IQGAP1 protein in the TCL reduced by approximately 60% compared with that in cells transfected with the control vector ( Figure 6C) ; a similar finding was observed in the CY. In addition, marginal amounts of IQGAP1 and p122RhoGAP/DLC-1 were detected in the PM, indicating that a decline in IQGAP1 decreased the recruitment of p122RhoGAP/DLC-1 to the cell membrane in response to ACh.
We treated skin fibroblasts with or without ionomycin at 10 -5 M for 5 min and investigated IQGAP1, p122RhoGAP/ DLC-1, and PLC-δ1 using fluorescence microscopy. PLC-δ1 and IQGAP1 not treated with ionomycin were detected as small spots in the cytoplasm and nucleus ( Figure 6D, a-c) .
For further investigation, we selected two extended flat areas of the cell and combined the PLC-δ1 and IQGAP1 magnified images ( Figure 6D, d-f ). They were not colocalized in the PM. Next, PLC-δ1 and p122RhoGAP/DLC-1 not treated with ionomycin were also detected as small spots in the cytoplasm and nucleus ( Figure 6E , a-c). We selected two extended flat areas of the cell and combined the PLC-δ1 and p122RhoGAP/DLC-1 magnified images ( Figure 6E, d-f ). They were not colocalized in the PM. After 5-min treatment with ionomycin at 10 -5 M, PLC-δ1 was detected as small dots in the cytoplasm and nucleus ( Figure 6F, a) . We detected IQGAP1 as small dots in the cytoplasm and nucleus, primarily localized in the nucleus ( Figure 6F, b) . In addition, small dots of PLC-δ1 and IQGAP1 were colocalized predominantly in the cytoplasm and PMs, where they formed structures analogous to actin stress fibers ( Figure 6F, c) . For further investigation, we selected two extended flat areas of the cell and combined the PLC-δ1 and IQGAP1 magnified images. These findings suggested that small dots of PLC-δ1 and IQGAP1 were colocalized on a structure that resembled actin stress fibers ( Figure 6F , d-f), with a distribution similar to that typical of actin filaments; furthermore, they were colocalized in the PM (arrow; Figure 6F , g-i).
Likewise, we detected PLC-δ1 as small dots in the cytoplasm and nucleus ( Figure 6G, a) . In addition, p122RhoGAP/ DLC-1 was detected as small dots in the cytoplasm and nucleus, but primarily localized in the nucleus ( Figure 6G, b) . Accordingly, we selected one extended flat area of the cell and combined PLC-δ1 and p122RhoGAP/DLC-1 magnified images. Small dots of PLC-δ1 and p122RhoGAP/DLC-1 were colocalized predominantly in the cytoplasm, again forming structures similar to actin stress fibers; they were also detected in the PMs ( Figure 6G, d-f ).
| Regulation of RhoA activation by
IQGAP1 and p122RhoGAP/DLC-1
Reportedly, the binding of RhoA-GTP to IQGAP1 regulates RhoA, 31 and that p122RhoGAP/DLC-1 exhibits strong GAP activity for RhoA. 17 Thus, we assessed how the overexpression of IQGAP1 and p122RhoGAP/DLC-1 affects RhoA-GAP levels. When HEK293 cells were stimulated with fetal bovine serum (FBS), RhoA-GTP was markedly increased; conversely, the overexpression of IQGAP1 decreased RhoA-GTP (Figure 7 ). The amount of GTP bound to the FBS-stimulated Rho protein was elevated by 15.5 ± 3.7 times compared with that of control cells without stimulation ( Figure 7B ). The amount of GTP bound to the RhoA protein was reduced in p122RhoGAP/DLC-1-transfected cells compared with FBS-stimulated cells in control cells; however, this difference was not statistically significant. When HEK293 cells were transfected with IQGAP1, RhoA activation in FBS-stimulated cells was markedly decreased. We observed a trend toward lower RhoA-GTP levels in cells cotransfected with IQGAP1 and p122RhoGAP/DLC-1 compared with those transfected with IQGAP1 alone; however, this difference was not statistically significant. In summary, we examined molecules assisting the p122RhoGAP/DLC-1 protein and identified a scaffold protein IQGAP1. Next, we focused on the biological function of IQGAP1 and found IQGAP1 was elevated in skin fibroblasts from CSA patients and it enhanced the PLC activity and peak intracellular calcium concentration in response to acetylcholine. Further we found the three proteins form a complex and moves along the microtubules, and ionomycin, F I G U R E 7 IQGAP1 and p122RhoGAP/DLC-1 regulates the RhoA activation. A, HEK293 cells are subcultured in 6-cm Petri dishes and transfected with pcDNA3/RH-p122, pcDNA3/RH-IQGAP1, or empty vector. Cells are serum-starved for 16 h and stimulated with 20% fetal bovine serum (FBS) for 5 min for the Rho activation. Cell lysates are directly analyzed using Western blotting for p122RhoGAP/DLC-1, IQGAP1, and total RhoA (2% of input). GTP-bound Rho is isolated from cell lysates; RhoA-GTP bound to Rhotekin-RBD is assessed using Western blotting with a RhoA-specific antibody (bottom). B, Western blotting results from three independent experiments performed as in Figure 7A are analyzed by densitometry. The amount of endogenous RhoA-GTP (normalized to total RhoA) present in serum-starved, empty vector transfected cells is assigned a value of 1 
| DISCUSSION
To further our understanding of p122RhoGAP/DLC-1, we searched for partner molecules operating with it in this study. Accordingly, we conducted immunoprecipitation experiments with skin fibroblasts obtained from patients with CSA, using the anti-p122RhoGAP/DLC-1 antibody, and determined that IQGAP1 interacts with p122RhoGAP/DLC-1.
In addition, using pull-down experiments, we observed that IQGAP1-C interacts with p122RhoGAP/DLC-1 through the region including the START domain of p122RhoGAP/ DLC-1, whereas PLC-δ1 interacts with IQGAP1-N through the region including the CHD and WW domain of IQGAP1-N. Choi et al (2013) demonstrated by immunostaining that endogenous IQGAP1 was partially colocalized with GFP-PLC-δ1-PH. Yamaga et al (2008) reported that p122RhoGAP/ DLC-1 interacted with the PH domain of PLC-δ1 in a pulldown experiment using various deletion mutants of GSTfused PLC-δ1 as baits. Overall, these findings suggested that p122RhoGAP/DLC-1, IQGAP1, and PLC-δ1 form heteromeric protein complexes. In this study, we used ACh as a cell stimulant because it is extensively used clinically in provocation tests for coronary spasm. 26 The PLC activity and the ACh-induced increment in ]i response to ACh in HEK293 cells. These findings suggest that the p122RhoGAP/DLC-1, PLC-δ1, and IQGAP1 complex is vital for the calcium response activation. p122RhoGAP/DLC-1 interacts with the PH domain of PLC-δ1 to enhance its activity and produces, through the hydrolysis of PIP 2 , two second messengers, IP 3 and diacylglycerol. 17, 30 We found that IQGAP1 interacted with PLC-δ1 and that the IQGAP1 overexpression enhanced the PLC activity. These findings suggest that the direct binding of IQGAP1 to PLC-δ1 is crucial for the activation of PLC-δ1. As p122RhoGAP/DLC-1 binds to the PH domain of PLC-δ1 and activates PLC-δ1, it is essential to ascertain the domain of PLC-δ1 that binds IQGAP1-N, including the CHD and WW domains, in the future study. IQGAP1 is a ubiquitously expressed multimodular scaffold protein that interacts with various proteins in several cell types. [32] [33] [34] Scaffold proteins facilitate the assembly of signaling cascades by concurrent binding to multiple consecutive components in the signaling pathway; by doing so, they regulate the speed, specificity, intracellular localization, and amplification of signal propagation. 35 Scaffold proteins for the mitogen-activated protein kinase (MAPK) cascade were among the first to be discovered. 36 /calmodulin, E-cadherin, epidermal growth factor receptor, B-Raf, MAPK/ERK kinase1/2, ERK2, and Cdc42. 35 Caveolins are a family of integral membrane proteins that constitute the principal components of caveolae membranes and are involved in receptor-independent endocytosis. [41] [42] [43] The IQGAP1 colocalization with the prescribed caveolae marker protein, caveolin-1, has been established by confocal microscopy and proximity assay. 44 Yamaga et al (2004) reported that p122RhoGAP/DLC-1 binds caveolin-1 through the RhoGAP domain, and that the START domain could bind to cholesterol. Furthermore, in PC12 cells, the agonist-induced primary increase in Ca 2+ recruits PLC-δ1 into lipid rafts from other parts of the PM or the CY by other scaffold proteins. 45 In this study, we assessed the ionomycin-induced recruitment of p122RhoGAP/DLC-1, IQGAP1, and PLC-δ1 in skin fibroblasts by Western blotting and fluorescence microscopy, as well as the ACh-induced recruitment of these proteins in HEK293 cells by Western blotting. After treatment with ionomycin and ACh, the amount of p122RhoGAP/DLC-1 and PLC-δ1 in the CY decreased, whereas p122RhoGAP/DLC-1, IQGAP 1, and PLC-δ1 increased in the PM. Nevertheless, how the initial increase in intracellular Ca 2+ promotes the PM recruitment of PLC-δ1 remains unclear. Contrarily, this study revealed that IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 are recruited to the PM by ACh and ionomycin stimulation. IQGAP1 is a novel stimulating protein that complexes with p122RhoGAP/DLC-1 and PLC-δ1 to move to the PM and enhance the PLC activity. Figure 8 shows protein complexes formed by IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1. The PLC-δ1-binding site is located at IQGAP1 between aa residues 1 and 745; notably, this region includes a CHD and WW domain. The IQGAP1-C binds to the C-terminal region of p122RhoGAP/ DLC-1 between aa residues 802 and 1091. In addition, this region includes a START domain. As p122RhoGAP/DLC-1 interacts with the PH domain of PLC-δ1, the protein complex shown in Figure 8 microtubules. 32, 46 Moreover, fluorescent-labeled CLIP-170 and kinesin Kip2 have been shown to comigrate along individual microtubule. 47 Hence, IQGAP1 in the complex, perhaps, interacts with CLIP-170, which moves along microtubules by interacting with kinesin ( Figure 8 ). 46 PLC-δ1 in the lipid rafts "meets" p122RhoGAP to be activated in the presence of Ca 2+ , leading to the robust PIP 2 hydrolysis and forming clusters in the lipid rafts. Hydrolyzed IP 3 and diacylglycerol activate IP 3 R and transient receptor potential channels and further elevate the influx of Ca 2+ from voltage-gated calcium channels. Yamaga et al have investigated the recruitment of p122RhoGAP/DLC-1 and PLC-δ1 to lipid rafts using rat pheochromocytoma PC12 cells. The amount of PLC-δ1 in the lipid raft fractions increased after the carbamylcholine treatment, whereas p122RhoGAP/DLC-1 remained unchanged, suggesting that p122RhoGAP/DLC-1 is constitutively expressed in lipid rafts. 30 Kawai et al (2004) reported that endogenous p122RhoGAP/DLC-1 was observed at the tips of actin stress fibers. In this study, we investigated the recruitment of IQGAP, p122RhoGAP/DLC-1, and PLC-δ1 to the cell membrane using HEK293 cells and skin fibroblasts. In HEK293 cells, IQGAP1 and p122RhoGAP/DLC-1 clearly increased in the PM after the ACh treatment. Furthermore, in skin fibroblasts, the PM IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 clearly elevated following ionomycin treatment. We found the amount of p122RhoGAP/DLC-1 in the lipid raft fraction or PM differs based on the type of cells. In this study, immunostaining revealed that PLC-δ1 and IQGAP1 were colocalized on a structure that resembled actin stress fibers, with a distribution analogous to typical actin filaments after the ionomycin treatment in skin fibroblasts. We observed that the initial increase in intercellular Ca 2+ promoted the recruitment of IQGAP1, p122RhoGAP/DLC-1, and PLC-δ1 to the cell membrane. Nevertheless, how these molecules are released from microtubules and recruited to PMs or lipid rafts remains unclear, necessitating the elucidation of underlying mechanisms. The protein complex of IQGAP1, p122RhoGAP/ DLC-1, and PLC-δ1 increased in cells obtained from patients with CSA compared with those from control subjects, being associated with the enhanced PLC activity. Hence, IQGAP1 could be a novel stimulator for the PLC-δ1 activity through direct activation and transporting to the PM and may, thus, play a pivotal role in the CSA pathogenesis. The p122RhoGAP/DLC-1 protein performs another function, as a GAP activator for Rho. Reportedly, the Rhokinase inhibitor, fasudil, attenuated the constrictor response of the coronary artery to ACh and prevented the occurrence of chest pain in patients with CSA. 48 Through its GAP activity, p122RhoGAP/DLC-1 might antagonize the development of coronary spasm similar to the Rho-kinase inhibitor. Casteel et al (2012) reported that IQGAP1 also functions against Rho. IQGAP1-C (aa 863-1657) binds directly to RhoA; when 293T cells were cotransfected with epitopetagged RhoA and IQGAP1, the amount of GTP bound to the Rho protein almost doubled compared with control cells transfected with RhoA plus an empty vector. When MDA-MB-231 cells were transfected with an siRNA specific for IQGAP1, the IQGAP1 depletion markely declined the RhoA activation in FBS-stimulated cells. 31 Conversely, Bhattacharya et al (2014) reported that RhoA-GTP, the active form, was increased in human airway smooth muscle cells with the shRNA-mediated IQGAP1 knockdown. Some prior studies reported an elevation in the p122RhoGAP/ DLC-1 protein expression in cultured skin fibroblasts obtained from patients with CSA. 22 In addition, the IQGAP1 protein expression was increased in cultured skin fibroblasts obtained from patients with CSA in this study. We assessed the RhoA activity and the elevation in intracellular free Ca 2+ using IQGAP1-transfected cells. Transfection with IQGAP1 strongly decreased the RhoA activity compared with FBSstimulated controls, and its activity approached the level of unstimulated control HEK293 cells. These findings suggest that the IQGAP1 overexpression exerted a synergistic effect on the RhoA reduction. Overall, these findings suggest that the Rho-GAP cascade might compensate enhanced coronary spasm but not contribute to enhanced coronary spasm. 
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